methyl 5-hydroxytetrahydro-2H-pyran-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: methyl 5-hydroxytetrahydro-2H-pyran-2-carboxylate
• 英文别名: Methyl 5-hydroxytetrahydro-2H-pyran-2-carboxylate；methyl 5-hydroxyoxane-2-carboxylate
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: CXCJZYYIQBOFPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 5-hydroxytetrahydro-2H-pyran-2-carboxylate 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 methyl 5-oxotetrahydro-2H-pyran-2-carboxylate
  参考文献：
  名称：

  [EN] GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
  [FR] CYANOÉTHYLPYRAZOLOPYRIDONES À SUBSTITUTION GÉMINALE UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE

  摘要：

  这项即时发明提供了Formula (I)的化合物，这些化合物是JAK抑制剂，因此可用于治疗JAK介导的疾病，如类风湿关节炎、哮喘、慢性阻塞性肺病和癌症。

  公开号：

  WO2014146491A1

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] COMPOSÉS TRICYCLIQUES INNOVANTS SERVANT D'INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089797A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，该化合物是野生型异柠檬酸脱氢酶（IDH）抑制剂：(I)。本发明还涉及将此处描述的三环化合物用于潜在治疗或预防涉及一个或多个突变IDH酶的癌症。本发明还涉及包含这些化合物的组合物。本发明还涉及将这些组合物用于潜在预防或治疗此类癌症。
• GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS
  申请人：CHILDERS Matthew Lloyd

  公开号：US20160272632A1

  公开（公告）日：2016-09-22

  The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  本发明提供了一种公式（I）的化合物，它们是JAK抑制剂，因此可用于治疗由JAK介导的疾病，如类风湿性关节炎、哮喘、慢性阻塞性肺疾病和癌症。
• Tricyclic compounds as inhibitors of mutant IDH enzymes
  申请人：Fischer Christian

  公开号：US10442819B2

  公开（公告）日：2019-10-15

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，它是一种或多种突变 IDH 酶的抑制剂：(I)。本发明还涉及本文所述三环化合物在潜在治疗或预防涉及一种或多种突变 IDH 酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3226688A1

  公开（公告）日：2017-10-11
• TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3226688B1

  公开（公告）日：2020-07-01